Login / Signup

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.

Judith BalmañaPeter Andreas FaschingFergus J CouchSuzette DelalogeSana Intidhar Labidi-GalyJoyce O'ShaughnessyYeon Hee ParkAndrea F EisenBenoit YouHughes BourgeoisAnthony GoncalvesZoe KempAngela SwampillaiTomasz JankowskiJoo Hyuk SohnElena V PoddubskayaGuzel MukhametshinaSercan AksoyConstanta V TimchevaTjoung-Won Park-SimonA Anton TorresEllie JohnKatherine BariaIsabel GibsonKaren A Gelmonnull null
Published in: Breast cancer research and treatment (2023)
Clinical trials registration number: NCT03286842.
Keyphrases
  • metastatic breast cancer
  • clinical trial
  • randomized controlled trial
  • phase ii
  • breast cancer risk
  • double blind
  • phase iii